This Article is From Nov 02, 2021

WHO Panel To Decide On Covaxin Emergency Use On Wednesday

Bharat Biotech's Covaxin has demonstrated 77.8% effectiveness against symptomatic COVID-19 and 65.2% protection against the new Delta variant.

Advertisement
India News

Bharat Biotech said it has concluded final analysis of Covaxin efficacy from Phase-3 trials. (File)

New Delhi:

The Technical Advisory Group (TAG), an independent advisory panel of the World Health Organisation (WHO), has sought additional clarifications from Bharat Biotech, the manufacturer of Covaxin, in order to conduct a final Emergency Use Listing (EUL) risk-benefit assessment for global use of the vaccine.

Replying to an ANI query, a WHO official, "The TAG met on October 26, 2021, and decided to seek additional clarifications from the Covaxin manufacturers that are needed to conduct a final EUL risk-benefit assessment for global use of the vaccine."

"The TAG expects to receive these clarifications from the manufacturer by the end of this week and aims to reconvene for the final risk-benefit assessment on Wednesday, 3 November," read the statement from WHO.

The Technical Advisory Group for Emergency Use Listing (TAG-EUL) is an independent advisory group that provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure.

Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant. The Bharat Biotech said that it concluded the final analysis of Covaxin efficacy from Phase-3 trials.

Advertisement

Bharat Biotech's Covaxin and AstraZeneca and Serum Institute's Covishield are the two widely used vaccines in India.

Meanwhile, India's cumulative vaccination coverage crossed 107 crore.

Advertisement

The WHO has so far approved COVID-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson and Johnson - Janssen, Moderna, and Sinopharm for emergency use.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

Advertisement